Perioperative Versus Postoperative CapOX Chemotherapy for Locally Advanced Colon Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

1370 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-31

Study Completion Date

2027-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Adjuvant chemotherapy has been widely adopted worldwide for locally advanced colon cancer. However, more and more studies have found better efficacy and potential advantages of perioperative or neoadjuvant chemotherapy. The sooner the systemic chemotherapy is received, the better suppression it has on activity of tumor growth factors. Pre-operative chemotherapy may eliminate tiny metastases. It may also shrink the invasion of tumor before surgery, and thus reducing operational trauma and expediting recovery. With advances in radiology and tomography, staging before surgery is accurate enough to identify risks and prognosis for patients. The phase II trial conducted by our department has yielded encouraging results (N=47, CapeOX regimen, clinicaltrials.gov NCT02415829): after the neoadjuvant chemotherapy, no subject had disease progression, 68.1% subjects reached complete or partial response. Besides, the toxicity of neoadjuvant CapeOX chemotherapy was acceptable. The present randomized controlled phase III trial will be conducted to further compare efficacy and safety of the neoadjuvant and adjuvant CapeOX chemotherapy for patients with locally advanced resectable colon cancer in China. This study may have two periods, each will last for approximately 5 years. After the first period (n=994), if the results of the test group are better than the control group, the study will be terminated. Otherwise, the study will enter into period 2 (n=376) through selecting out genetically sensitive subjects and repeating the same trial process as period 1.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Postoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients

NCT01268943

Rectal Neoplasms

COMPLETED PHASE1

Apatinib for Resectable Colorectal Cancer

NCT03228043

Apatinib Outcome, Fatal Colorectal Cancer +2 more

WITHDRAWN NA

Adjuvant Chemotherapy in Patients With Clinical Stage III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy

NCT03415763

Rectal Neoplasms

RECRUITING PHASE3

Neoadjuvant Immunotherapy in Locally Advanced Colon Cancers

NCT05833672

Colon Cancer Immunotherapy

NOT_YET_RECRUITING PHASE2

Adjuvant Treatment of Concurrent RT and CAPOX or Capecitabine Alone for Stage II and III Rectal Cancer

NCT00714077

Rectal Neoplasms

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Locally Advanced Colon Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Open label

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Perioperative chemotherapy with CapOX regimen

Group Type EXPERIMENTAL

capecitabine plus oxaliplatin before and after surgery

Intervention Type DRUG

Subjects will receive systemic CapeOX chemotherapy both before and after the radical surgery for at most 4 cycles respectively. They shall have rest after the surgery for at least four weeks before the post-operative chemotherapy. CapOX regimen will be administered as follows:

1. Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1
2. Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14
3. Repeat every 3 weeks (Q3W)

Postoperative chemotherapy with CapOX regimen

Group Type ACTIVE_COMPARATOR

capecitabine plus oxaliplatin after surgery

Intervention Type DRUG

Subjects will first receive radical surgery, then have rest for at least four weeks. Thereafter, subjects will receive systemic CapeOX chemotherapy for at most 8 cycles. CapOX regimen will be administered as follows:

1. Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1
2. Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14
3. Q3W

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

capecitabine plus oxaliplatin before and after surgery

Subjects will receive systemic CapeOX chemotherapy both before and after the radical surgery for at most 4 cycles respectively. They shall have rest after the surgery for at least four weeks before the post-operative chemotherapy. CapOX regimen will be administered as follows:

1. Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1
2. Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14
3. Repeat every 3 weeks (Q3W)

Intervention Type DRUG

capecitabine plus oxaliplatin after surgery

Subjects will first receive radical surgery, then have rest for at least four weeks. Thereafter, subjects will receive systemic CapeOX chemotherapy for at most 8 cycles. CapOX regimen will be administered as follows:

1. Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1
2. Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14
3. Q3W

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2;
* Adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements conducted within 7 days of starting study treatment: Neutrophil count≥1.5×109/L, Platelet count≥100×109/L, Hemoglobin≥80g/L, Serum bilirubin≤24umol/L, Alanine aminotransferase and aspartate aminotransferase ≤ 60×IU/L, Serum creatinine≤110 umol/L;
* No current pregnancy or breast-feeding, and subjects at childbearing age shall take method of contraception ;
* Be in a condition to receive a surgery/procedure;
* No second tumor at present or in the past 5 years, except skin basal cell carcinoma, skin squamous cell carcinoma, or any in situ cancer;
* No previous systemic chemotherapy for treating colon cancer;
* No other chemotherapy at the same time;
* Expected lifetime longer than three months;
* Be willing and able to understand the study and to provide written informed consent.

Exclusion Criteria

* End-stage cachexia patients;
* Cardiopulmonary dysfunction or liver and kidney dysfunction, and unable to tolerate CapeOX chemotherapy;
* Metastatic carcinoma;
* Moderate or above anemia caused by serious local tumor bleeding;
* Incomplete or complete intestinal obstruction;
* Known to be allergic to oxaliplatin or capecitabine;
* Active hepatitis, severe coagulation disorder patients;
* Pregnant or lactating women; or women who have fertility but have not taken at taken adequate contraceptive measures;
* Known to have deficient dihydropyrimidine dehydrogenase (DPD)；
* Have vital organ failure or other severe diseases, including but not limited to coronary heart disease, cardiovascular diseases, or myocardial infarction within 12 months before being included; severe neurological or psychiatric history；severe infection; active disseminated intravascular coagulation;
* Unable or unwilling to abide by the study plan.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No